- Reports /
- Aspiration & Biopsy Needles Market
Aspiration & Biopsy Needles Market
Aspiration & Biopsy Needles Market Market Research Report – Segmented By Product (Biopsy Needles, Aspiration Needles), By Procedure (Image-Guided Procedures, Nonimage-Guided Procedures), By Site (Breast, Lung, Colorectal, Prostate, Kidney, Bone and Bone Marrow, Other Sites), By Region (North America, Europe, APAC, Rest of World (RoW)) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Product
- By Procedure
- By Site
- By Region
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
Aspiration & Biopsy Needles Market was valued at US $942.80 million in 2021 and is projected to grow at 7.71% CAGR over the forecast period to reach US $1,472.31 million by 2027. Aspiration & Biopsy Needles Market represented US $130.17 million opportunity over 2019-2021 and estimated to create US $529.51 million opportunity in 2027 over 2021.
Aspiration & Biopsy Needles from Consainsights analyses the Aspiration & Biopsy Needles Market in the Life Sciences industry over the forecast period to 2027.
Aspiration & Biopsy Needles research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Aspiration & Biopsy Needles segmentation includes Product, Procedure, Site, Region and Geography.
Based on the Product, the Aspiration & Biopsy Needles analysis covers Biopsy Needles, Aspiration Needles.
In Product segment, Biopsy Needles segment has highest cagr growth of 6.83%.
Based on the Procedure, the Aspiration & Biopsy Needles analysis covers Image-Guided Procedures, Nonimage-Guided Procedures.
In Procedure segment, Image-Guided Procedures segment has highest cagr growth of 6.83%.
Based on the Site, the Aspiration & Biopsy Needles analysis covers Breast, Lung, Colorectal, Prostate, Kidney, Bone and Bone Marrow, Other Sites.
In Site segment, Breast segment has highest cagr growth of 6.83%.
Based on the Region, the Aspiration & Biopsy Needles analysis covers North America, Europe, APAC, Rest of World (RoW).
In Region segment, North America segment has highest cagr growth of 6.83%.
Based on the region, the Aspiration & Biopsy Needles analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include Argon Medical Devices, Inc., Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cardinal Health, Inc., CONMED Corporation, Cook Group Incorporated, HAKKO CO.,LTD Medical Device Division, INRAD Inc., Medtronic, Plc, Merit Medical Systems, Olympus Corporation, Ranfac Corporation, Remington Medical Inc., Somatex Medical Technologies, Stryker Corporation and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Product
Introduction
In 2021, Biopsy Needles segment has the highest revenue of US $848.95 million and is expected to grow at CAGR of 6.83% by 2027 Biopsy Needles segment has highest cagr growth of 6.83%.
Biopsy Needles
Biopsy Needles segment was valued at US $731.74 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $1,325.75 million by 2027. Biopsy Needles segment represented US $117.21 million opportunity over 2019-2021 and estimated to create US $476.80 million opportunity in 2027 over 2021.
Aspiration Needles
Aspiration Needles segment was valued at US $80.90 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $146.56 million by 2027. Aspiration Needles segment represented US $12.96 million opportunity over 2019-2021 and estimated to create US $52.71 million opportunity in 2027 over 2021.
Procedure
Introduction
In 2021, Image-Guided Procedures segment has the highest revenue of US $766.82 million and is expected to grow at CAGR of 6.83% by 2027 Image-Guided Procedures segment has highest cagr growth of 6.83%.
Image-Guided Procedures
Image-Guided Procedures segment was valued at US $660.95 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $1,197.49 million by 2027. Image-Guided Procedures segment represented US $105.87 million opportunity over 2019-2021 and estimated to create US $430.67 million opportunity in 2027 over 2021.
Nonimage-Guided Procedures
Nonimage-Guided Procedures segment was valued at US $151.68 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $274.82 million by 2027. Nonimage-Guided Procedures segment represented US $24.30 million opportunity over 2019-2021 and estimated to create US $98.84 million opportunity in 2027 over 2021.
Site
Introduction
In 2021, Breast segment has the highest revenue of US $374.40 million and is expected to grow at CAGR of 6.83% by 2027 Breast segment has highest cagr growth of 6.83%.
Breast
Breast segment was valued at US $322.71 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $584.68 million by 2027. Breast segment represented US $51.69 million opportunity over 2019-2021 and estimated to create US $210.28 million opportunity in 2027 over 2021.
Lung
Lung segment was valued at US $205.67 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $372.63 million by 2027. Lung segment represented US $32.95 million opportunity over 2019-2021 and estimated to create US $134.02 million opportunity in 2027 over 2021.
Colorectal
Colorectal segment was valued at US $126.40 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $229.01 million by 2027. Colorectal segment represented US $20.25 million opportunity over 2019-2021 and estimated to create US $82.36 million opportunity in 2027 over 2021.
Prostate
Prostate segment was valued at US $82.19 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $148.92 million by 2027. Prostate segment represented US $13.17 million opportunity over 2019-2021 and estimated to create US $53.56 million opportunity in 2027 over 2021.
Kidney
Kidney segment was valued at US $52.59 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $95.27 million by 2027. Kidney segment represented US $8.42 million opportunity over 2019-2021 and estimated to create US $34.27 million opportunity in 2027 over 2021.
Bone and Bone Marrow
Bone and Bone Marrow segment was valued at US $18.01 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $32.63 million by 2027. Bone and Bone Marrow segment represented US $2.89 million opportunity over 2019-2021 and estimated to create US $11.74 million opportunity in 2027 over 2021.
Other Sites
Other Sites segment was valued at US $5.06 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $9.16 million by 2027. Other Sites segment represented US $0.81 million opportunity over 2019-2021 and estimated to create US $3.30 million opportunity in 2027 over 2021.
Region
Introduction
In 2021, North America segment has the highest revenue of US $507.41 million and is expected to grow at CAGR of 6.83% by 2027 North America segment has highest cagr growth of 6.83%.
North America
North America segment was valued at US $437.35 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $792.39 million by 2027. North America segment represented US $70.06 million opportunity over 2019-2021 and estimated to create US $284.98 million opportunity in 2027 over 2021.
Europe
Europe segment was valued at US $177.18 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $321.00 million by 2027. Europe segment represented US $28.38 million opportunity over 2019-2021 and estimated to create US $115.45 million opportunity in 2027 over 2021.
APAC
APAC segment was valued at US $109.81 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $198.95 million by 2027. APAC segment represented US $17.59 million opportunity over 2019-2021 and estimated to create US $71.55 million opportunity in 2027 over 2021.
Rest of World (RoW)
Rest of World (RoW) segment was valued at US $88.30 million in 2019 and is projected to grow at 6.83% CAGR over the forecast period to reach US $159.97 million by 2027. Rest of World (RoW) segment represented US $14.14 million opportunity over 2019-2021 and estimated to create US $57.53 million opportunity in 2027 over 2021.